| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Alkyl-Chain
Sulfo-NHS-Acetate sodium targets primary amine groups (-NH₂) on proteins, peptides, and amine-containing molecules; it acylates lysine residues and N-termini, blocking positive charges and altering protein properties; it does not have a biological receptor target. |
|---|---|
| ln Vitro |
The ligand of E3 ubiquitin ligase and the ligand of the target protein are the two distinct ligands found in PROTAC, which are joined by a linker. Specifically, target proteins are degraded by PROTAC through the intracellular ubiquitin-proteasome system [1].
In vitro, Sulfo-NHS-Acetate sodium is used to acetylate proteins and peptides; the reaction proceeds efficiently at pH 7-9 in aqueous buffers; acetylation neutralizes positive charges on lysine residues, which can affect protein stability, activity, and interactions. |
| ln Vivo |
In vivo, Sulfo-NHS-Acetate sodium is not administered as a therapeutic agent; it is used as a chemical tool for modifying proteins and biomolecules in research applications; its water-soluble sulfo group reduces membrane permeability, limiting its use to extracellular modifications.
|
| Enzyme Assay |
Non-cellular assay procedure: Sulfo-NHS-Acetate sodium is dissolved in aqueous buffer (e.g., PBS, pH 7.4) at a desired concentration; the protein or peptide substrate is added; the reaction mixture is incubated at room temperature for 30-60 minutes; excess reagent is removed by desalting or dialysis; the degree of acetylation is determined by mass spectrometry or by quantifying remaining free amines using a colorimetric assay (e.g., TNBSA assay).
|
| Cell Assay |
Cellular assays: Sulfo-NHS-Acetate sodium is used to modify cell surface proteins by reacting with extracellular amine groups; cells are treated with the reagent in PBS at 4°C to prevent internalization; acetylation of surface proteins is confirmed by flow cytometry using amine-reactive fluorescent probes or by Western blotting; effects on receptor function or cell signaling can be assessed.
|
| Animal Protocol |
In vivo animal experiments are not typically conducted with Sulfo-NHS-Acetate sodium as it is a chemical modification reagent rather than a therapeutic or diagnostic agent; it may be used ex vivo to modify proteins prior to administration in animal studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable for Sulfo-NHS-Acetate sodium as it is a reactive chemical reagent and not administered systemically; it is hydrolyzed in aqueous solution and does not have pharmacological applications.
|
| Toxicity/Toxicokinetics |
Toxicological profile: Sulfo-NHS-Acetate sodium is a reactive chemical that can cause skin and eye irritation; it should be handled with appropriate personal protective equipment; it is not intended for human or animal consumption; standard safety precautions for handling reactive NHS esters apply.
|
| References | |
| Additional Infomation |
Other information: Sulfo-NHS-Acetate sodium is a water-soluble analog of NHS-Acetate; the sulfo group enhances water solubility and reduces membrane permeability; it is used in protein chemistry to study the role of lysine residues in protein function, to improve protein stability, and to prepare acetylated standards for mass spectrometry.
|
| Molecular Formula |
C6H7NO7S.NA
|
|---|---|
| Molecular Weight |
260.177
|
| Exact Mass |
258.976
|
| CAS # |
221222-61-3
|
| Related CAS # |
Sulfo-NHS-Acetate;152305-87-8
|
| PubChem CID |
23709683
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
16
|
| Complexity |
425
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1CC(=O)N(OC(=O)C)C1=O)(O)(=O)=O.[NaH]
|
| InChi Key |
VGYOVKDAMGIIJU-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C6H7NO7S.Na/c1-3(8)14-7-5(9)2-4(6(7)10)15(11,12)13;/h4H,2H2,1H3,(H,11,12,13);/q;+1/p-1
|
| Chemical Name |
sodium;1-acetyloxy-2,5-dioxopyrrolidine-3-sulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8435 mL | 19.2175 mL | 38.4349 mL | |
| 5 mM | 0.7687 mL | 3.8435 mL | 7.6870 mL | |
| 10 mM | 0.3843 mL | 1.9217 mL | 3.8435 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
